Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study

To see complete record on, please visit this link

Id: NCT05306899

Organisation Name: University Health Network, Toronto

Overal Status: Recruiting

Start Date: June 1, 2022

Last Update: October 18, 2022

Lead Sponsor: University Health Network, Toronto

Brief Summary: Chronic daily headaches (CDH) poses a significant burden on patients, healthcare systems and the society. Intravenous (IV) ketamine infusion, an intervention that is widely available and scalable, can treat CDH by reversing receptor-mediated sensitization. This study is a multicenter, placebo-controlled, parallel group randomized trial with blinding of participants and observers with the goal of comprehensively assessing the effect of high-dose IV ketamine infusion (1 for six hours) on the frequency and intensity of headaches, mood, activity, sleep, quality of life and safety of ketamine for three months after the interventions. Use of validated questionnaires, wearable technology, a research team that includes investigators with expertise in studying ketamine and in evaluating treatments for CDH and pain syndromes are some of the unique features of this project.

Our study aims to prospectively assess the efficacy and safety of high-dose intravenous ketamine infusions compared to saline infusions in participants with CDH syndrome.

  • Chronic Daily Headache

Total execution time in seconds: 0.19765901565552